Grant: Master's Award: Canada Graduate Scholarships
University of Guelph
$17,500.00
The Impact of Human Milk Oligosaccharides on the Gut Microbiota and Type-1 Diabetes
EF 2022-23
Résumé
Over the past few decades, global incidence rates of Type 1 diabetes (T1D) have been rapidly increasing and is expected to double worldwide over the next decade. T1D onset is most common in childhood; however, there is an increasing trend for the development of T1D at earlier ages. Majority of T1D cases carry predisposed genetic risk factors. However, only 3-7% of genetically susceptible individuals develop T1D, highlighting the influence of environmental factors on T1D pathogenesis. Human milk consumption during infancy is a known dietary influence as studies have shown this has a protective role against T1D development. Human milk oligosaccharides (HMOs) confer several beneficial functions to infant development. In breastfed infants, dominant species of gut microbes that can utilize HMOs have a growth advantage over those which are unable to. Recent findings from the Allen-Vercoe lab have shown various growth strategies used by a wide diversity of bacteria isolated from infant fecal samples in presence of pooled HMOs (pHMOs). Several strains experienced (pHMO)-induced growth inhibition, demonstrating a novel and seemingly specific antimicrobial property of HMOs. I hypothesize that pHMO-induced growth inhibition will be found across the spectrum of human gut-associated phyla and will occur through several modes of action. My objectives are to 1) determine the impact of pHMOs on the growth properties of gut microbes through HMO assays and 2) determine if the mechanism of action of inhibition is bactericidal or bacteriostatic using differential fluorescence. This research will provide greater insight into the nature of pHMO-induced growth inhibition on the gut microbiome and contribute to understanding the microbiome-shaping activity of HMOs in breastmilk.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486608
Name
Athithan Panuya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Impact of Human Milk Oligosaccharides on the Gut Microbiota and Type-1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Microbial Properties; Auto-Immune Diseases; Bioinformatics; Breast Milk; Gut Microbiota; Human Microbiome; Human Milk Oligosaccharides; Induced Growth Inhibition; Proteomics; Type 1 Diabetes
Abstract
Over the past few decades, global incidence rates of Type 1 diabetes (T1D) have been rapidly increasing and is expected to double worldwide over the next decade. T1D onset is most common in childhood; however, there is an increasing trend for the development of T1D at earlier ages. Majority of T1D cases carry predisposed genetic risk factors. However, only 3-7% of genetically susceptible individuals develop T1D, highlighting the influence of environmental factors on T1D pathogenesis. Human milk consumption during infancy is a known dietary influence as studies have shown this has a protective role against T1D development. Human milk oligosaccharides (HMOs) confer several beneficial functions to infant development. In breastfed infants, dominant species of gut microbes that can utilize HMOs have a growth advantage over those which are unable to. Recent findings from the Allen-Vercoe lab have shown various growth strategies used by a wide diversity of bacteria isolated from infant fecal samples in presence of pooled HMOs (pHMOs). Several strains experienced (pHMO)-induced growth inhibition, demonstrating a novel and seemingly specific antimicrobial property of HMOs. I hypothesize that pHMO-induced growth inhibition will be found across the spectrum of human gut-associated phyla and will occur through several modes of action. My objectives are to 1) determine the impact of pHMOs on the growth properties of gut microbes through HMO assays and 2) determine if the mechanism of action of inhibition is bactericidal or bacteriostatic using differential fluorescence. This research will provide greater insight into the nature of pHMO-induced growth inhibition on the gut microbiome and contribute to understanding the microbiome-shaping activity of HMOs in breastmilk.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Athithan, Panuya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~